Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. - Wikidata - awgldk - TriplyDB

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

http://www.wikidata.org/entity/Q46486664

about

Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea Bench-to-bedside review: Clostridium difficile colitis Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins Clostridium difficile Infection in Children: Current State and Unanswered Questions Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review Overuse of antimicrobial prophylaxis in community practice urology.Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection Diversity and Evolution in the Genome of Clostridium difficile Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond Predictors of Clostridium difficile colitis infections in hospitals Metabolism of bile salts in mice influences spore germination in Clostridium difficile The changing epidemiology of Clostridium difficile infections The challenges posed by reemerging Clostridium difficile infection.Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis Immune responses to Clostridium difficile infection Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.Use of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial Clostridium difficile infection.Prevalence of diverticulosis in recurrent Clostridium difficile infection Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.The potential value of Clostridium difficile vaccine: an economic computer simulation model.Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea Clostridium difficile Infections: What Every Clinician Should Know Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea.Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.Risk Factors for Delayed Recurrence of Clostridium difficile Infection Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study

P2860

Q24234630-F69B869A-A476-40CB-839A-E083AF326C48 Q24644191-4C3E3AF7-261C-422B-9C85-FEF819674BF5 Q24676310-31F8EE92-A4D2-4231-A841-8BEE3EABD0E5 Q26767079-F1E45313-F3E3-439A-B0F7-15FCCC705404 Q26771995-0FB9977A-D255-4F4A-81C1-4D01511820AA Q26775010-140FC4DC-BEAB-4038-B7B9-5EA210AAA420 Q27016320-FDCE438D-D814-4E31-AE7A-23BBBB6BB91F Q27021390-95E3D001-4EE8-42FE-B731-C49B1154CD70 Q27308931-DE63B60B-34EB-48BF-810C-5DDABBD568BB Q28084026-D4FA7EE9-5E66-499F-9C50-02AE46EA3FA1 Q28084700-F0DD6470-B97A-4675-95FA-F25C79E2D28F Q28084737-D828438A-9180-4D18-9AE3-83DFE842DFEC Q28395557-C0E9C550-7849-4837-859F-C54E818E93F0 Q28472543-C28C8872-FBF5-4609-A87C-8BA58A8B0BDA Q28750385-05F650B6-5B01-48DF-9102-0CBB9D51E437 Q30229530-6FC43DF2-84B0-4F29-87F1-45B6FB794915 Q30354419-B5F13ACC-E3C9-4B3F-9CE0-B23AFB9972EE Q30412148-CE3E4655-DFF9-4A02-9944-4B5BD22CB42B Q30416692-1751E916-EB33-4227-9210-C3D852FD8D9B Q30417830-3E4F5BC0-7403-48B1-9284-A5C5FD4C3F21 Q30425705-30FF8C07-85C5-4B19-BC2D-D63D3D806AB7 Q33276804-FC78B6A7-21FB-4917-BCC0-D4C13B490B37 Q33285304-84FFBE89-EB47-4B38-B812-537C90BAA776 Q33398747-8E7F3F14-6953-4EF6-B637-E8F1471FEB6A Q33508665-9DCF1CBE-781F-4B29-9A94-8C30D8AD6DC2 Q33596510-AE6747B1-3259-42D3-BD6A-07710CD6ADB2 Q33782277-D3586065-1927-4DBF-94E0-EA0B9970B6F3 Q33810999-05D1FDE8-363A-4E19-9367-3F2E19B715F1 Q33890323-20DD84B3-DE5B-466E-B6BC-B4AFA18F760C Q33990521-BF9182C4-792C-4869-BF74-DE04729C67DF Q34012314-1BE5544F-B6E5-4BD1-8938-648FDF5C3E18 Q34018277-65F68473-001E-48AE-958F-19C31A59114D Q34028301-897B88B0-3D42-411B-8B19-E0AC676E2AC7 Q34072892-169F793E-C46E-4C70-B5FC-54151AC4FED5 Q34099215-8B3F3EEC-33F2-4C57-826C-96172FD30C9D Q34206660-9449F16B-6663-4309-8EC4-C90D5B54B499 Q34306091-FCD62993-A95C-4F0F-93F6-00BBE3529B96 Q34409185-7EA5C89F-B47C-4D11-94D7-80F9C861FCC7 Q34429596-E516BBE5-EED8-4B1D-804F-6FB2E0B5CE60 Q34429629-E5E6C9CB-2C84-44E4-94F5-1E93682DF883

P2860

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

http://www.wikidata.org/entity/Q46486664

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@en

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@nl

type

label

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@en

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@nl

prefLabel

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@en

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@nl

P1433

Q46486664-9A4ECA2A-DD70-40DC-84E7-D78669A76DF9

P1476

Q46486664-939E8568-C0C9-4840-940F-859E50CD9F3E

P2093

Q46486664-5C3BE9B7-BBE1-493B-B843-D2DC4D0E0945

Q46486664-7CEA322A-D0DB-4420-AF61-D22403330816

Q46486664-999F6F9F-DE76-4589-948E-7FBCC2CB3AE2

Q46486664-A34645FD-04E5-4D1C-8BE7-6153ABC010AD

Q46486664-B5EF2936-4A98-44E6-82C5-CA2ED3628B79

Q46486664-D8897C80-9FFE-40AC-A55E-C9AD941644E0

Q46486664-DA6B5BA9-029D-4CD8-9D8E-C3A9A828E617

P2860

Q46486664-194CE9E9-7192-42F6-8702-69BF17661B5C

Q46486664-1DC553FE-6AA4-409F-97B0-5AC900DCBB33

Q46486664-21E0D7A1-84E1-411F-94DE-5008157B1C21

Q46486664-288B84C4-F10B-4E01-AB27-8C2702A0F048

Q46486664-2B2430DA-A66E-40B2-A20F-C13F8B931602

Q46486664-2F5237B2-2818-44E4-AF13-D695C5CAA340

Q46486664-33BE37F3-1620-4616-A65C-5A251379D11A

Q46486664-3DA4EB4B-2B5F-4644-98E6-C4A16B56F8B7

Q46486664-67EA1D07-A5DB-4ACF-8508-4B6883BD0E88

Q46486664-6A930F7D-41B6-41F4-8124-B75055A08FA0

P304

Q46486664-55BF5D1B-E245-44F5-B82B-7955A62ACD31

P31

Q46486664-6CB67BBD-E403-47BD-BFD4-36E92D633430

P356

Q46486664-EE44FE35-B504-4F41-A4A0-12D5E4B82E55

P407

Q46486664-D2A52FE5-EC7E-4B10-BD81-03AF10C0650A

P433

Q46486664-3ABB51C7-92EB-4D4E-BD37-B55F88BF23F3

P478

Q46486664-876F03E6-4233-415E-92C4-8E067436E4F5

P50

Q46486664-19950CF3-30D1-4637-94B3-4699AD541C20

P577

Q46486664-270A5435-4550-4F02-BFF6-83058BD8D826

P5875

Q46486664-43C44893-9D7A-493F-A6C4-4A757B0A97F8

P698

Q46486664-8D54F586-3F1F-4883-9093-68136DAD3862

P921

Q46486664-0A0E3361-2C85-46DB-B221-7631986994A7

Q46486664-8500E72C-26CB-48B4-8809-F27F746E4781

P356

P1433

Clinical Infectious Diseases

P1476

Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.

@en

P2093

Claude Bourassa

http://www.w3.org/2001/XMLSchema#string

Dominique Godin

http://www.w3.org/2001/XMLSchema#string

Evelyne Raiche

http://www.w3.org/2001/XMLSchema#string

Jacques Pepin

http://www.w3.org/2001/XMLSchema#string

Joannie Ruel

http://www.w3.org/2001/XMLSchema#string

Katalin Fulop

http://www.w3.org/2001/XMLSchema#string

Marie-Eve Alary

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.

Clinical practice. Antibiotic-associated diarrhea.

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy.

In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria

Clostridium difficile infection: responses, relapses and re-infections.

P304

1591-1597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/430315

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Louis Valiquette

P577

2005-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7852644

http://www.w3.org/2001/XMLSchema#string

P698

15889355

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile